NCT05803928View on ClinicalTrials.gov

Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies

PHASE1RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

November 1, 2024

Study Completion Date

April 1, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

lenvatinib + anti-PD-1 antibodies

A ablation treatment group B ablation+ lenvatinib + anti-PD-1 antibodies treatment group

PROCEDURE

ablation

radiofrequency ablation or microwave ablation

Trial Locations (1)

510000

RECRUITING

Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Hua Li

OTHER